Eli Lilly and Company: Schizophrenia trials
The registry lists 33 Schizophrenia studies with Eli Lilly and Company as lead sponsor. 2 are open to participants now and 9 have results posted.
Phase 1 3Phase 2 4Phase 3 10Phase 4 16No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Brenipatide in Adult Participants With SchizophreniaRecruitingNCT07410507Phase 2
- Zyprexa® Relprevv™ Patient Care ProgramEnrolling by invitationNCT01088386
- Study in Adolescents With Schizophrenia or Bipolar DisorderCompletedNCT00982020Phase 4Results posted
- A Study of Olanzapine in Patients With SchizophreniaCompletedNCT00970281Phase 3Results posted
- A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With SchizophreniaCompletedNCT00640510Phase 3Results posted
- Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With OlanzapineCompletedNCT00401973Phase 3Results posted
- Efficacy Study of Early Onset of Antipsychotic Drug Action in SchizophreniaCompletedNCT00337662Phase 4Results posted
- Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With SchizophreniaCompletedNCT00320489Phase 3Results posted
- Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)CompletedNCT00303602Phase 4Results posted
- Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective DisorderCompletedNCT00190749Phase 4Results posted
- Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT00088465Phase 3Results posted
- An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.CompletedNCT00510211
- Weight Gain Management in Patients With SchizophreniaCompletedNCT00486005Phase 4
- Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With SchizophreniaCompletedNCT00485901Phase 3
- Assessment of a Weight Management Program for Weight Gain in Patients With SchizophreniaCompletedNCT00485823Phase 4
- Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With SchizophreniaCompletedNCT00485810Phase 1/2
- Managing Acute Schizophrenia, a Comparison Between Two Atypical AntipsychoticsCompletedNCT00485498Phase 4
- Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible TabletCompletedNCT00324051Phase 4
- A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With SchizophreniaCompletedNCT00316238Phase 2
- Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic TreatmentCompletedNCT00191555Phase 4
- Olanzapine Treated Adolescents With Schizophrenia or Bipolar I DisorderCompletedNCT00113594Phase 3
- Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With SchizophreniaCompletedNCT00103571Phase 4
- Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective DisorderCompletedNCT00100776Phase 4
- Pharmacokinetic Characterization of Intramuscular Olanzapine DepotCompletedNCT00094640Phase 1
- Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective DisorderCompletedNCT00090012Phase 4
- A Combination of Two Currently Approved Drugs to Enhance the Treatment of SchizophreniaCompletedNCT00089869Phase 1/2
- Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With SchizophreniaCompletedNCT00088491Phase 3
- Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With SchizophreniaCompletedNCT00088478Phase 3
- Study of Olanzapine vs. Aripiprazole in the Treatment of SchizophreniaCompletedNCT00088049Phase 4
- Olanzapine Versus Placebo in the Treatment of Adolescents With SchizophreniaCompletedNCT00051298Phase 3
- The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I DisorderCompletedNCT00044187Phase 4
- Olanzapine Versus An Active Comparator in the Treatment of SchizophreniaCompletedNCT00036088Phase 4
- Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With SchizophreniaCompletedNCT00034801Phase 4